Thermo Fisher Scientific is trading 3.03% up at $632.28, extending its 4.16% gain on August 19 after a Q2 earnings beat and raised 2026 revenue and adjusted EPS outlook.
- Q2 revenue reached $11.99 billion, while adjusted EPS was $6.03; management cited stronger customer activity and improved operating leverage.
- Healthcare rotation supported the move, with XLV up 3.23% despite broader U.S. indexes trading lower.